Product logins

Find logins to all Clarivate products below.


Formulary Advantages in Atrial Fibrillation: How Will MCO Size Affect the Design of Factor Xa Formularies?

In the coming years, atrial fibrillation (AF) patients will increasingly have more choice for anticoagulation therapy. Although Boehringer Ingelheim’s Pradaxa (dabigatran etexilate) and emerging factor Xa inhibitors will offer clinical advantages over warfarin, their high prices will likely be the greatest obstacle to patient access. Using tiering and restrictions data from Fingertip Formulary and insight from 50 pharmacy directors, we discuss the key trends in reimbursement of AF therapies, the drivers of these trends, and how stakeholders can capitalize on future shifts in coverage to beat the competition.

Related Market Access Reports

Report
Executive Briefing | Bricks, Mortar and Benefit Design in the Age of Payment Bundling | December 2011
HealthLeaders-InterStudy has prepared an executive briefing.
Report
Pharmacy Benefit Evaluator 2.0 | Data | July 2011
Report
Executive Briefing | Is Insurance Strife In NYC A Sign Of Reform Future? | November 2011
HealthLeaders-InterStudy has prepared an executive briefing.
Report
Formulary Advantages in Type 2 Diabetes:Rebates and discounts dictate the formulary position of branded therapies among some U.S. health plans.
According to the Centers for Disease Control and Prevention (CDC), an estimated 25.8 million people in the United States have diabetes. Diabetes is the leading cause of kidney failure, nontraumatic lo…
Report
CIGNA | 3Q 2011 | Health Plan Earnings Summaries
The HealthLeaders-InterStudy Market Analyst team analyzes major developments at the nation’s publicly held health plans each quarter through their financial releases and conference call transcripts. T…